PMGC Holdings (ELAB) Asset Writedowns and Impairment (2024 - 2026)
PMGC Holdings (ELAB) posted Asset Writedowns and Impairment of $463421.0 for Q1 2026, up 104.29% sequentially from $226841.0 in Q4 2025, and up 4684.94% YoY from $9685.0 in Q1 2025.
PMGC Holdings (ELAB) Asset Writedowns and Impairment (2024 - 2026) Analysis & Trends
PMGC Holdings has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $463421.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment rose 4684.94% year-over-year to $463421.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $714703.0 (up 5.57% YoY) and the FY2025 annual result came in at $253922.0, down 63.0% from the prior year.
- Asset Writedowns and Impairment grew to $463421.0 in Q1 2026 per ELAB's latest filing, from $226841.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $629266.0 in Q3 2024 and troughed at $9685.0 in Q1 2025.
- A 3-year average of $198040.1 and a median of $23318.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2025 and 2026: Asset Writedowns and Impairment sank 49.01% in 2025, then jumped 4684.94% in 2026.
- Over 3 years, Asset Writedowns and Impairment stood at $14756.0 in 2024, then jumped by 1437.28% to $226841.0 in 2025, then soared by 104.29% to $463421.0 in 2026.
- According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $463421.0, $226841.0, and $9685.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 463,421.00 |
| Mar 31, 2026 | 463,421.00 |
| Dec 31, 2025 | 226,841.00 |
| Dec 31, 2025 | 226,841.00 |
| Mar 31, 2025 | 9,685.00 |
| Mar 31, 2025 | 9,685.00 |
| Dec 31, 2024 | 14,756.00 |
| Dec 31, 2024 | 14,756.00 |
| Sep 30, 2024 | 629,266.00 |
| Sep 30, 2024 | 629,266.00 |
| Jun 30, 2024 | 23,318.00 |
| Jun 30, 2024 | 23,318.00 |
| Mar 31, 2024 | 18,994.00 |
| Mar 31, 2024 | 18,994.00 |